These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 9644506)
1. A new alternative to estrogen: raloxifene. Runowicz C Health News; 1998 Jun; 4(8):4. PubMed ID: 9644506 [No Abstract] [Full Text] [Related]
2. Raloxifene for postmenopausal osteoporosis. Med Lett Drugs Ther; 1998 Mar; 40(1022):29-30. PubMed ID: 9529516 [No Abstract] [Full Text] [Related]
3. From blunderbuss to magic bullet? Alderman C Nurs Stand; 1998 Jan 21-27; 12(18):18. PubMed ID: 9485842 [No Abstract] [Full Text] [Related]
4. Raloxifene: a new class of anti-estrogens for the prevention of osteoporosis. Kupecz D Nurse Pract; 1998 Sep; 23(9):91-3. PubMed ID: 9778672 [No Abstract] [Full Text] [Related]
5. Raloxifene: designer estrogen for preventing postmenopausal osteoporosis. Park L; Evans MF Can Fam Physician; 1999 May; 45():1191-3. PubMed ID: 10349062 [No Abstract] [Full Text] [Related]
6. Raloxifene: a selective estrogen receptor modulator. Scott JA; Da Camara CC; Early JE Am Fam Physician; 1999 Sep; 60(4):1131-9. PubMed ID: 10507743 [TBL] [Abstract][Full Text] [Related]
7. Effects of raloxifene in postmenopausal women. Cole RC; Flaws JA; Bush TL N Engl J Med; 1998 Apr; 338(18):1313; author reply 1313-4. PubMed ID: 9565492 [No Abstract] [Full Text] [Related]
8. Clinical efficacy of SERMs. Dere WH Aging (Milano); 1998 Apr; 10(2):160-1. PubMed ID: 9666217 [No Abstract] [Full Text] [Related]
9. New drug approved to help prevent osteoporosis. Mayo Clin Health Lett; 1998 Mar; 16(3):3. PubMed ID: 9516369 [No Abstract] [Full Text] [Related]
10. Effects of raloxifene in postmenopausal women. Friedman MN N Engl J Med; 1998 Apr; 338(18):1313; author reply 1313-4. PubMed ID: 9565493 [No Abstract] [Full Text] [Related]
11. [Agonists-antagonists of estrogens, their potential use in prophylaxis and treatment of osteoporosis]. Hoszowski K Pol Tyg Lek; 1995 Nov; 50(44-47):41-2. PubMed ID: 8643425 [TBL] [Abstract][Full Text] [Related]
12. [Current trends in prevention and therapy of postmenopausal osteoporosis]. Rossi G Recenti Prog Med; 1998 Jun; 89(6):288. PubMed ID: 9658894 [No Abstract] [Full Text] [Related]
13. Tissue-specific estrogens--the promise for the future. Fuleihan GE N Engl J Med; 1997 Dec; 337(23):1686-7. PubMed ID: 9385130 [No Abstract] [Full Text] [Related]
19. I am 51 years old, perimenopausal, have irritable bowel syndrome and a family history of breast cancer, and am told my bones are thinning. These conditions would seem to rule out my use of estrogen or Fosamax. I weight train and take 1,500 mg of calcium a day to stave off osteoporosis. What's left? Robb-Nicholson C Harv Womens Health Watch; 1998 Nov; 6(3):8. PubMed ID: 9814138 [No Abstract] [Full Text] [Related]
20. Next generation of SERMs being seen in clinic. Smigel K J Natl Cancer Inst; 1997 Jul; 89(13):913. PubMed ID: 9214669 [No Abstract] [Full Text] [Related] [Next] [New Search]